A patient recently told me she'd been getting semaglutide injections from a telehealth app — no labs, no follow-up, no provider who knew anything about her history. She'd lost weight, yes. She'd also lost nearly 18 pounds of muscle mass, developed a gallstone, and had no idea either of those things had happened until she came to us.
This is the GLP-1 landscape right now. Extraordinary drugs, extraordinary results — and an equally extraordinary amount of unsupervised, poorly managed use that is causing real harm to real patients.
We want to give you the science so you can understand what these medications actually do, what the risks look like without proper oversight, and what medically supervised GLP-1 therapy means in practice.
What Is a GLP-1 Receptor Agonist?
GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut naturally produces in response to eating. Its job is to tell your pancreas to release insulin, signal your brain that you're full, slow gastric emptying so nutrients are absorbed more gradually, and suppress glucagon (the hormone that raises blood sugar).
GLP-1 receptor agonists are synthetic molecules that bind to those same receptors and activate them — more potently, and for much longer, than your natural GLP-1 does. The result is a cascade of metabolic effects that go well beyond what most patients expect.
Semaglutide vs. Tirzepatide: What's the Difference?
Both are GLP-1 agonists, but they work somewhat differently:
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Avg. weight loss (clinical trials) | ~15% of body weight | ~20–22% of body weight |
| Insulin sensitivity | Improved | Significantly improved (GIP adds synergy) |
| Muscle preservation | Moderate | Better (with appropriate protein & resistance training) |
| FDA approvals | T2DM, obesity, cardiovascular risk reduction | T2DM, obesity |
Tirzepatide's dual-agonist mechanism — activating both GLP-1 and GIP receptors — appears to produce superior insulin sensitization and somewhat better preservation of lean muscle mass. For our patients in pain management who often have significant deconditioning, this matters enormously.
The Mechanisms That Actually Matter
Most people think of GLP-1 drugs as appetite suppressants. That's true — but it undersells the pharmacology by a wide margin.
Central Appetite Regulation
GLP-1 receptors are abundant in the hypothalamus and brainstem — the regions that regulate hunger, satiety, and reward-related eating. These drugs don't just make you feel full faster at meals. They appear to reduce the neural reward response to high-calorie foods. Patients consistently describe food differently: "I just don't think about it the same way anymore." That's not willpower. That's neuropharmacology.
Direct Anti-Inflammatory Effects
This is the mechanism we find most clinically exciting from our pain management background. GLP-1 agonists have demonstrated direct anti-inflammatory effects — independent of weight loss — in multiple tissue types. They reduce macrophage activation, suppress NF-κB signaling (a master regulator of inflammation), and decrease circulating levels of CRP and IL-6. For patients with inflammatory pain, this is not a side benefit. It's potentially central to their response.
Cardiovascular Protection
The SELECT trial (2023) was a landmark: semaglutide reduced major adverse cardiovascular events by 20% in people with obesity and established cardiovascular disease — even in people without type 2 diabetes. The mechanism isn't fully understood, but involves reduced inflammation, improved endothelial function, and direct cardiac effects. This is why GLP-1 therapy in the right patient isn't just about aesthetics. It's about lifespan.
Slowed Gastric Emptying
Food stays in your stomach longer. This flattens the post-meal glucose curve, reduces hunger between meals, and contributes significantly to weight loss. It's also the mechanism behind the most common side effects — nausea, constipation, and, in improperly managed cases, more serious gastrointestinal complications.
"GLP-1 therapy done right is one of the most powerful metabolic interventions we have available. GLP-1 therapy done without labs, titration, and monitoring is a different thing entirely — and we see the consequences."
What Happens Without Medical Supervision
The online GLP-1 market has exploded. Telehealth platforms offering semaglutide prescriptions with a five-minute questionnaire. Compounding pharmacies shipping peptides to anyone with a credit card. We're not naive about why this happened — access to these medications was genuinely limited, and the demand vastly outpaced the healthcare system's capacity to provide it responsibly.
But the risks of unsupervised use are real:
- Muscle loss: Without adequate protein intake (1.2–1.6g/kg/day minimum) and resistance training, patients on GLP-1 agonists lose significant lean muscle mass. This worsens metabolic rate long-term and is especially dangerous in older adults
- Gallstones: Rapid weight loss dramatically increases cholelithiasis risk. Patients need to know this and monitor for symptoms
- Inadequate titration: The dose-escalation schedule exists for a reason. Rushing it increases GI side effects and dropout rates
- Pancreatitis: Rare but real. A thorough history (personal or family history of pancreatitis, medullary thyroid carcinoma, or MEN2) is essential before prescribing
- Rebound weight gain: Without behavioral support and a transition plan, 60–70% of patients regain most of their weight within a year of stopping. The medication is a tool, not a cure
What "medically supervised" actually means at Salt & Serum
Before we prescribe anything, we run a comprehensive metabolic panel, thyroid function, lipid panel, HbA1c, and a full history including GI and family history. We start low and titrate slow. We monitor labs at regular intervals. We build in a protein and resistance training protocol from day one. And we're available — not just a portal message — when patients have questions.
Who Is the Right Candidate?
GLP-1 therapy is appropriate for a wide range of patients — not just those who are significantly overweight. The right candidates include adults with:
- BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, T2DM, sleep apnea, dyslipidemia)
- Established insulin resistance or prediabetes, even with a "normal" BMI
- Cardiovascular risk factors where the cardioprotective effects of GLP-1 agonists are clinically relevant
- Inflammatory conditions where systemic inflammation from excess adiposity is contributing to symptoms
There are also clear contraindications — which is precisely why a prescriber who knows your full history is not optional.
The Bottom Line
GLP-1 agonists are among the most clinically significant developments in metabolic medicine in decades. The science is real, the results are real, and the potential to transform health outcomes — not just body weight — is genuinely exciting.
But they are prescription medications that work through powerful physiological mechanisms. They require baseline labs, individualized dosing, ongoing monitoring, and a clinical relationship where someone is accountable for your outcomes.
If you've been curious about GLP-1 therapy — or if you've tried it before without the oversight it deserves — we'd like to have that conversation.
GLP-1 therapy done right
Comprehensive labs, individualized dosing, real follow-up — and two APRNs who will actually pick up the phone. Start with a personalized consultation.
Book a Consultation